InterMune (NASDAQ: ITMN) was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday.
Several other analysts have also recently commented on the stock. Analysts at UBS AG (NYSE: UBS) initiated coverage on shares of InterMune in a research note to investors on Thursday, April 12nd. They set a “neutral” rating and a $13.50 price target on the stock. Separately, analysts at Brean Murray cut their price target on shares of InterMune from $42.00 to $37.00 in a research note to investors on Monday, April 9th. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of InterMune in a research note to investors on Monday, April 9th.
InterMune traded up 0.66% on Friday, hitting $10.388. InterMune has a 52-week low of $9.67 and a 52-week high of $45.37. The company’s market cap is $678.7 million.
The company last announced its quarterly results on Thursday, April 26th. It reported ($0.74) earnings per share (EPS) for the previous quarter, missing the Thomson Reuters consensus estimate of ($0.70) EPS by $0.04. The company’s quarterly revenue was up 39.1% on a year-over-year basis. Analysts expect that InterMune will post $-0.76 EPS next quarter.
InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and fibrotic diseases.